

# Management of Male Breast Cancer: ASCO Guideline

Michael J. Hassett, MD, MPH<sup>1</sup>; Mark R. Somerfield, PhD<sup>2</sup>; Elisha R. Baker, PhD<sup>3</sup>; Fatima Cardoso, MD<sup>4</sup>; Kari J. Kansal, MD<sup>5</sup>; Dylan C. Kwait, MD<sup>6</sup>; Jennifer K. Plichta, MD, MS<sup>7</sup>; Charité Ricker, MS<sup>8</sup>; Anna Roshal, MD<sup>9</sup>; Kathryn J. Ruddy, MD, MPH<sup>10</sup>; Joshua D. Safer, MD<sup>11</sup>; Catherine Van Poznak, MD<sup>12</sup>; Rachel L. Yung, MD<sup>13</sup>; and Sharon H. Giordano, MD, MPH<sup>14</sup>

## abstract

**PURPOSE** To develop recommendations concerning the management of male breast cancer.

**METHODS** ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process.

**RESULTS** Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations.

**RECOMMENDATIONS** Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Breast magnetic resonance imaging is not recommended routinely. Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer.

**J Clin Oncol 38.** © 2020 by American Society of Clinical Oncology

## ASSOCIATED CONTENT

### Appendix

#### Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on November 26, 2019 and published at [ascopubs.org/journal/jco](https://ascopubs.org/journal/jco) on February 14, 2020; DOI <https://doi.org/10.1200/JCO.19.03120>

Reprint Requests: 2318 Mill Road, Suite 800, Alexandria, VA 22314; [guidelines@asco.org](mailto:guidelines@asco.org).

Additional information is available at [www.asco.org/breast-cancer-guidelines](http://www.asco.org/breast-cancer-guidelines).

## INTRODUCTION

Male breast cancer is a rare disease representing < 1% of all breast carcinomas diagnosed in the United States each year. In 2019, an estimated 2,670 new cases of breast cancer were expected to be diagnosed among men in the United States, and about 500 men were expected to die as a result of breast cancer.<sup>1</sup> The lifetime risk of breast cancer is about 1:1,000 for a man, whereas it is approximately 1:8 for a woman. Breast cancer incidence rates rise steadily with age in men as they do in women; however, the average age of a new breast cancer diagnosis is five years older for men (67 years) than for women (62 years). Other risk factors for male breast cancer include a family history of breast cancer; black ethnicity; exposure to radiation to the breast or chest; carrying a predisposition

germline genetic mutation (eg, *BRCA2*, *BRCA1*, *CHEK2*, *PALB2*); use of exogenous estrogen; and diseases associated with hyperestrogenism (eg, Klinefelter's syndrome).<sup>2</sup>

There are substantial knowledge gaps concerning the optimal management of breast cancer in men. To date, approaches to treating men with breast cancer have been extrapolated largely from research conducted in women with breast cancer. Planned or ongoing treatment trials that focus on men should eventually inform the standard of care, but they are years from completion and will not address all important questions for male breast cancer. This American Society of Clinical Oncology (ASCO) guideline offers recommendations on several key aspects of the management of male breast cancer.

## THE BOTTOM LINE

### Management of Male Breast Cancer: ASCO Guideline

#### Guideline Question

What is the optimal management for men with breast cancer including use of adjuvant endocrine therapy, use of endocrine therapy for advanced or metastatic disease, targeted therapies, management of treatment-related adverse effects, genetic testing, and post-treatment surveillance?

#### Target Population

Men diagnosed with invasive breast cancer.

#### Target Audience

Medical oncologists, radiologists, radiation oncologists, surgical oncologists, endocrinologists, oncology nurses, patients/caregivers/advocates, oncology advanced practice providers, genetic counselors.

#### Methods

An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Guideline development involved a formal consensus process.

#### Results of Phase I—The Breast Cancer Advisory Group Guideline Survey

The Advisory Group reported high-level consensus that the following components of management were largely the same for men and women: (1) use of gene expression profile testing to guide adjuvant treatment decision making (eg, Oncotype DX and prognostic tests), (2) primary surgery, (3) adjuvant chemotherapy, (4) adjuvant radiation therapy, and (5) chemotherapy for advanced/metastatic disease.

Based on these findings, the Expert Panel recommends that, for men with breast cancer, the approach to the use of gene expression profile testing to guideline adjuvant treatment decision making, to primary surgery, to adjuvant chemotherapy, to adjuvant radiation therapy, and to chemotherapy for advanced/metastatic disease should be the same as the approach used for women.

#### Results of Phase II—The Expert Panel Consensus Development Process

The Consensus Development Process focused on topics for which the Advisory Group and Expert Panel did not believe there was already widespread agreement that the management of men and women was largely the same: (1) endocrine therapy in the adjuvant setting, (2) endocrine therapy in the metastatic setting, (3) management of adverse effects from endocrine therapy, (4) germline genetic testing, (5) survivorship care, and (6) the use of targeted therapies for advanced/metastatic disease. Over two rounds of ratings, 12 recommendations pertaining to 10 clinical questions derived from these six topics satisfied the required 75% consensus agreement threshold.

#### Recommendations

**Recommendation 1.1.** Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Recommendation 1.2.** Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy but have a contraindication to tamoxifen may be offered gonadotropin-releasing hormone agonist/antagonist and an aromatase inhibitor (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 2.1.** Men who are treated with adjuvant endocrine therapy should be treated for an initial duration of five years (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Recommendation 2.2.** Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of tamoxifen therapy (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Recommendation 3.** Men with early-stage breast cancer should not be treated with bone-modifying agents to prevent recurrence but could still receive these agents to prevent or treat osteoporosis (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 4.1.** Men with advanced or metastatic, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer should be offered endocrine therapy as first-line therapy except in cases of visceral crisis or rapidly progressive disease. Options include tamoxifen, an aromatase inhibitor with a gonadotropin-releasing hormone agent, and fulvestrant. Cyclin-dependent kinase 4/6 inhibitors can be used in men as they are used in women (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

(continued on following page)

## THE BOTTOM LINE (CONTINUED)

**Recommendation 4.2.** Men who develop recurrent metastatic, hormone receptor–positive, HER2–negative breast cancer while receiving adjuvant endocrine therapy should be offered an alternative endocrine therapy except in cases of visceral crisis or rapidly progressive disease (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Recommendation 4.3.** Endocrine therapy for men with advanced or metastatic, hormone receptor–positive, HER2–negative breast cancer may be sequenced as in women (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 5.** Targeted therapy guided by HER2, programmed death ligand 1, PIK3CA, and germline *BRCA* mutation status may be used in the treatment of advanced or metastatic male breast cancer using the same indications and combinations that are offered to women (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong). (Targeted therapy based on hormone receptor status is addressed in Recommendations 4.1 to 4.3.)

**Recommendation 6.1.** Management of endocrine therapy toxicity is similar to the approach used for women (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 6.2.** Testosterone/androgen supplementation should not be used by men with breast cancer (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 7.** Physicians should counsel patients about the symptoms of recurrence including new lumps, bone pain, chest pain, dyspnea, abdominal pain, or persistent headaches. The risk of breast cancer recurrence continues through 15 years after primary treatment and beyond. Continuity of care for patients with breast cancer is recommended and should be performed by a physician experienced in the surveillance of patients with cancer and in breast examination, including the examination of irradiated breasts (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 8.** Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy, if technically feasible, regardless of genetic predisposition (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Recommendation 9.1.** Contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 9.2.** Breast magnetic resonance imaging is not recommended routinely in men with a history of breast cancer (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Recommendation 10.** Male patients with breast cancer should be offered genetic counseling and genetic testing for germline mutations (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

### Draft Recommendations That Did Not Reach the Required 75% Consensus Threshold

Two draft recommendations did not exceed the required 75% consensus agreement threshold: (1) contralateral annual mammography in men without a predisposing genetic mutation and (2) chemoprevention. In accordance with the modified Delphi approach used by ASCO, the Expert Panel could not issue formal consensus recommendations for these clinical questions.

### Additional Resources

More information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources, is available at [www.asco.org/breast-cancer-guidelines](http://www.asco.org/breast-cancer-guidelines). Patient information is available at [www.cancer.net](http://www.cancer.net).

**ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.**

## SCOPE OF THE GUIDELINE

In foundational work, the Expert Panel (Appendix Table A1, online only) identified 14 core management components for male breast cancer and chose to develop the guideline using a two-phase consensus development process. In phase I, the Expert Panel identified aspects of breast cancer care for which treatment of men and women was likely to be the same, using a survey of content experts from ASCO's Breast Cancer Guideline Advisory Group. The survey asked two questions regarding each management component. First, how strongly do you agree that the approach to care is largely the same for men and women

(using a 5-point scale from “strongly agree” to “strongly disagree”)? Second, would it be important to address this component of management in a male breast cancer guideline (“yes” v “no”)?

Detailed findings of the Breast Cancer Advisory Group survey are presented in the Results section. Briefly, the Breast Cancer Advisory Group reported high-level consensus that the following components of management were largely the same for men and women: (1) use of gene expression profile testing to guide adjuvant treatment decision making (eg, Oncotype DX and prognostic tests), (2) primary surgery, (3) adjuvant chemotherapy, (4) adjuvant

radiation therapy, and (5) chemotherapy for advanced/metastatic disease. For these aspects of management, ASCO recommends that the approach used for men should be the same as the approach used for women.

The Breast Cancer Advisory Group did not identify consensus that treatment of men and women should be the same for five components of management: (1) endocrine therapy in the adjuvant setting, (2) endocrine therapy in the metastatic setting, (3) management of adverse effects from endocrine therapy, (4) germline genetic testing, and (5) survivorship care. These five topics, combined with an additional topic identified by the Expert Panel, became the focus of phase II of the consensus development process, in which a dedicated Expert Panel used the modified Delphi method to develop guideline recommendations.

## GUIDELINE QUESTIONS

This clinical practice guideline addresses 10 clinical questions, which were derived from the six components of management described previously: (1) Which adjuvant endocrine therapy should be offered to men with early-stage, hormone receptor–positive breast cancer? (2) What is the optimal duration of adjuvant endocrine treatment of men with early-stage, hormone receptor–positive breast cancer? (3) What is the role of bone-modifying agents in men with early-stage, hormone receptor–positive breast cancer? (4) Which endocrine therapies should be offered to men with advanced or metastatic, hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer? (5) What is the role of cyclin-dependent kinase (CDK) inhibitors and mammalian target of rapamycin inhibitors in the treatment of men with advanced or metastatic breast cancer? (6) What is the optimal approach to managing toxicity of endocrine therapy in men with breast cancer? (7) What guidance around follow-up and management should be available to men who have been previously treated for breast cancer? (8) What testing is recommended for the detection of breast cancer after curative-intent primary therapy for patients who are not germline mutation carriers of breast cancer susceptibility genes? (9) How should post-treatment surveillance recommendations differ for men with breast cancer who carry predisposing germline mutations in breast cancer susceptibility genes? (10) Should referral for genetic counseling and genetic testing for germline mutations be recommended for newly diagnosed male patients with breast cancer?

## METHODS

### Guideline Development Process

This systematic review–based, formal consensus guideline was developed by a multidisciplinary Expert Panel, which included a patient representative and an ASCO guidelines staff member with health research methodology expertise.

The Expert Panel met in person and via teleconference and corresponded through e-mail. Based on the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. The guideline recommendations were sent for an open comment period of two weeks allowing the public to review and comment on the recommendations after they submitted a confidentiality agreement. These comments were taken into consideration while finalizing the recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then circulated for external review and submitted to *Journal of Clinical Oncology* for editorial review and consideration for publication. All ASCO guidelines are ultimately reviewed and approved by the Expert Panel and the ASCO Clinical Practice Guidelines Committee prior to publication. All funding for the administration of the project was provided by ASCO.

The recommendations were developed based on a systematic review of the literature and clinical experience. The literature review involved a search of PubMed for the period of January 1, 1998, through September 20, 2019. The search string was adopted from the literature search that informed the National Cancer Institute's Physician Data Query cancer information summary about male breast cancer treatment. The search was broad and included clinical trials; systematic reviews and meta-analyses; case-control studies; case series; cohort studies; and a wide range of outcomes including survival, toxicity, and patient-reported outcomes. Genetic mutation and "BRCA" search terms were also included.

Articles from the search were included if they reported data on outcomes of endocrine therapy in men with breast cancer; on the prevalence and/or management of endocrine therapy adverse effects in men treated for breast cancer; on clinical, pathologic, or prognostic features of breast cancer in men; on the risk of subsequent cancers among men diagnosed with a first primary breast cancer; or on the frequency of germline genetic mutations in men with breast cancer. Reports of case series were included if the series included  $\geq 20$  patients treated in the adjuvant setting or  $\geq 10$  patients treated in the metastatic setting. Articles were excluded from the systematic review if they were (1) meeting abstracts not subsequently published in peer-reviewed journals; (2) single case studies; (3) editorials, commentaries, letters, news articles, narrative reviews; or (4) published in a non-English language. A guideline implementability review was conducted. Based on the implementability review, revisions were made to the draft to clarify recommended actions for clinical practice.

Because of the limited evidence available for most of the clinical questions, recommendations were developed using the ASCO modified Delphi formal consensus methodology.<sup>3</sup> This process involved the drafting of recommendations by

a subgroup of the Expert Panel using clinical expertise and the available evidence. The Expert Panel (n = 13) met in person to review and refine the recommendations. The Expert Panel was then supplemented by additional experts (n = 21), who were recruited to rate their agreement with the recommendations. The entire membership of 34 experts is referred to as the Consensus Panel. Each recommendation had to be agreed to by at least 75% of Consensus Panel respondents to be accepted. Ratings for the type and strength of recommendation and quality of evidence are provided with each recommendation. A “strong” rating was assigned when the observed consensus agreement was between 90% and 100%; otherwise, a “moderate” rating was assigned. This methodology is described in further detail elsewhere ([www.asco.org/guideline-methodology](http://www.asco.org/guideline-methodology)).

The ASCO Expert Panel and guidelines staff will work with co-chairs to keep abreast of any substantive updates to the guideline. Based on formal review of the emerging literature, ASCO will determine the need to update. The ASCO Guidelines Methodology Manual (available at [www.asco.org/guideline-methodology](http://www.asco.org/guideline-methodology)) provides additional information about the guideline update process. This is the most recent information as of the publication date.

#### Guideline Disclaimer

The Clinical Practice Guidelines and other guidance published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations reflect high, moderate, or low confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as is” basis and makes no

warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

#### Guideline and Conflicts of Interest

The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at <https://www.asco.org/rwc>). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

## RESULTS

### Results of Breast Cancer Guidelines Advisory Group Survey

The goal of the ASCO Breast Cancer Guidelines Advisory Group Survey was to distinguish between components of management for which there was widespread consensus that the approach for men and women was largely the same versus those for which widespread consensus did not exist, with the intention that the Guideline Panel would focus its work on the latter topics. Using data from the survey of the ASCO Breast Cancer Guidelines Advisory Group, the Expert Panel used the following thresholds to identify components of management for which there was not widespread agreement: (1) at least 25% of respondents disagreed with the statement that the management of men and women with breast cancer was largely the same, and (2) at least 25% of respondents reported that addressing the component of management in the male breast cancer guideline was important (Table 1).

The survey asked respondents to comment on 14 components of management. The Breast Cancer Guideline Advisory Group reported high-level consensus that five components of management were largely the same for men and women: (1) use of gene expression profile testing to guide adjuvant treatment decision making (eg, Oncotype DX and prognostic tests),<sup>4</sup> (2) primary surgery, (3) adjuvant chemotherapy, (4) adjuvant radiation therapy, and (5) chemotherapy for advanced/metastatic disease. Consequently, these components of care were not further

**TABLE 1.** Survey of ASCO Breast Cancer Guidelines Advisory Group Members to Identify Areas of Pre-Existing Consensus and Refine Topics to be Addressed by the Expert Panel

Breast Cancer Management Approach	Proportion Agreeing That the Approach "Is Largely the Same" for Men and Women (%)	Proportion Reporting that It Is Important For the Guideline to Address this Topic (%)
High-level agreement		
Gene expression profile testing (eg, Oncotype DX, MammaPrint)	100	NR
Adjuvant chemotherapy	91	58
Chemotherapy for advanced/metastatic disease	91	42
Adjuvant radiation therapy	84	42
Primary surgery	75	58
<b>Lower-level agreement and high-level importance</b>		
<b>Hormone therapy for advanced/metastatic disease</b>	<b>45</b>	<b>83</b>
<b>Post-treatment surveillance</b>	42	67
<b>Adjuvant hormone therapy</b>	27	100
<b>Management of adverse effects from endocrine therapy</b>	25	75
<b>Genetic testing</b>	0	100
Lower-level agreement and lower-level importance		
Neoadjuvant chemotherapy	50	NR
Psychosocial support	24	58
Neoadjuvant hormone therapy	8	NR
Breast reconstruction	8	8

NOTE. Bold highlights aspects of breast cancer management on which the Expert Panel focused.

Abbreviation: NR, not reported due to low response rate in the survey.

addressed by the Expert Panel. The Breast Cancer Guideline Advisory Group reported a lack of consensus with and a high degree of importance to address five components of management: (1) endocrine therapy in the adjuvant setting, (2) endocrine therapy in the metastatic setting, (3) management of adverse effects from endocrine therapy, (4) germline genetic testing, and (5) survivorship care. These components formed the foundation of the Expert Panel's work.

The Breast Cancer Guideline Advisory Group and Expert Panel identified four components of management rated as having a low level of importance for inclusion in the male breast cancer guideline: (1) neoadjuvant chemotherapy, (2) neoadjuvant endocrine therapy, (3) breast reconstruction, and (4) psychosocial support. These components were not addressed in the guideline. Last, the Expert Panel elected to address the use of targeted chemotherapy for advanced/metastatic disease. While the Guideline Advisory Group reported a high level of consensus that chemotherapy use was substantially similar for men and women, the Expert Panel judged that the relative novelty and high cost associated with targeted treatments warranted their inclusion.

## Literature Review Results

A total of 26 descriptive reports or observational studies met the eligibility criteria and form the evidentiary basis for the guideline recommendations. The studies included in the review are summarized in the Data Supplement Tables 1-5 (online only). Twelve studies addressed endocrine treatment in men with breast cancer<sup>5-16</sup>; four addressed the prevalence and/or management of endocrine therapy adverse effects<sup>17-20</sup>; six reported on clinical, pathologic, and prognostic features of breast cancer in men<sup>21-26</sup>; two addressed the risk of second breast cancers in men<sup>27,28</sup>; and two addressed the frequency of germline pathogenic and likely pathogenic variants (ie, mutations) in hereditary cancer predisposition genes, such as *BRCA1* and *BRCA2*, in men with breast cancer.<sup>29,30</sup>

## Results of the Formal Consensus Development Process

As mentioned, because of the limitations of the available evidence, the guideline relied on a formal consensus development process to generate practice recommendations. During an in-person meeting, the Expert Panel drafted 19 recommendations pertaining to 10 clinical questions. Then, the full Consensus Panel conducted two rounds of

voting. During the first round, agreement with the individual recommendations ranged from 50% to 100% (N = 34 respondents).

Only two of the 19 recommendations did not reach the required 75% agreement threshold, and another two achieved a marginal level of agreement at 75%. All four of these recommendations were revised based on comments from the Consensus Panel's first round of voting. These four revised recommendations underwent a second round of voting with the full Consensus Panel. A recommendation pertaining to genetic counseling and testing had inadvertently been omitted from round 1 of voting, so it was reviewed with the four revised guideline recommendations in round 2.

Agreement with the recommendations in round 2 ranged from 58.07% to 96.77% (n = 31 respondents). Results for each of the recommendations and each round of voting are provided in the Data Supplement. Two recommendations did not exceed the required 75% threshold: (1) contralateral annual mammography and (2) chemoprevention. Consequently, these two recommendations were excluded from the practice recommendations that follow, although the topics are addressed in the Discussion.

## FORMAL CONSENSUS RECOMMENDATIONS

### CLINICAL QUESTION 1

Which adjuvant endocrine therapy should be offered to men with early-stage, hormone receptor–positive breast cancer?

#### Recommendation 1.1

Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

#### Recommendation 1.2

Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy but have a contraindication to tamoxifen may be offered gonadotropin-releasing hormone (GnRH) agonist/antagonist and an aromatase inhibitor (AI; Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** Most male breast cancers are hormone receptor positive; about 99% are estrogen receptor positive and about 81% are progesterone receptor positive.<sup>26</sup> Adjuvant endocrine therapy is thus the mainstay of systemic treatment in men with early-stage breast cancer. Tamoxifen is the preferred adjuvant endocrine therapy based on observational studies that have suggested a survival benefit.<sup>12,24,25</sup>

Data on the use of AIs in the treatment of men with early-stage breast cancer are sparse. Population-based series comparing AI and tamoxifen have reported inferior survival

among men with breast cancer who were treated with an AI.<sup>9,10,24</sup> For this reason, treatment of men with an AI alone is generally not preferred. However, use of an AI in combination with a GnRH analog is an acceptable alternative, especially for men who have a contraindication to tamoxifen (eg, a history of thrombosis).<sup>17</sup> Adding the GnRH analog may help overcome the lack of complete estradiol suppression sometimes seen in men treated with an AI alone.<sup>2</sup> Some have argued in favor of using an AI alone in selected patients, such as those who are unlikely to tolerate combined therapy, although concerns about the efficacy of this approach persist.

### CLINICAL QUESTION 2

What is the optimal duration of adjuvant endocrine treatment of men with early-stage, hormone receptor–positive breast cancer?

#### Recommendation 2.1

Men who are treated with adjuvant endocrine therapy should be treated for an initial duration of five years (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

#### Recommendation 2.2

Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence based on considerations of recurrence risk using established prognostic factors (eg, nodal status, tumor size and grade)<sup>31</sup> may be offered an additional five years of tamoxifen therapy (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Literature review and analysis.** There is no evidence from clinical trials in men with breast cancer to inform clinical questions regarding the duration of adjuvant endocrine therapy. These recommendations represent the best clinical opinion of the Expert Panel based on personal experience in the management of male breast cancer and extrapolation from studies conducted in women with early-stage breast cancer.<sup>31,32</sup> Of note, tamoxifen use in men with breast cancer can be associated with treatment-limiting adverse effects,<sup>33</sup> which can lead to low adherence, treatment discontinuation,<sup>18</sup> and a greater risk of recurrence and death.<sup>20</sup> Additional research on the effects of long-term tamoxifen use in men with breast cancer is warranted.

### CLINICAL QUESTION 3

What is the role of bone-modifying agents in preventing recurrence in men with early-stage, hormone receptor–positive breast cancer?

#### Recommendation 3

Men with early-stage breast cancer should not be treated with bone-modifying agents to prevent recurrence but could still receive these agents to prevent or treat osteoporosis. (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** There is no evidence from clinical trials in men with breast cancer to inform clinical questions regarding the use of bone-modifying agents to prevent breast cancer recurrence. The Expert Panel based its recommendation on the following considerations: (1) studies of bone-modifying agents among women have demonstrated somewhat inconsistent findings; (2) there is as yet no Food and Drug Administration (FDA) indication for bone-modifying agents among women in this clinical setting; (3) the benefit of bone-modifying agents in women appears to be most prominent among those who are postmenopausal and receiving AIs<sup>34</sup>; and (4) most men receive tamoxifen. This recommendation represents the best clinical opinion of the Expert Panel based on personal experience in the management of male breast cancer and extrapolation from studies in women. Preservation of bone health remains a long-term clinical challenge in patients with breast cancer. Additional research is needed to establish any potential benefits before recommending the use of bone-modifying agents to prevent the recurrence of early breast cancer.

#### CLINICAL QUESTION 4

Which endocrine therapies should be offered to men with advanced or metastatic, hormone receptor–positive, HER2–negative breast cancer?

##### Recommendation 4.1

Men with advanced or metastatic, hormone receptor–positive, HER2–negative breast cancer should be offered endocrine therapy as first-line therapy except in cases of visceral crisis or rapidly progressive disease. Options include tamoxifen, an AI with a GnRH agent, and fulvestrant. CDK 4/6 inhibitors can be used in men as they are used in women (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

##### Recommendation 4.2

Men who develop recurrent metastatic, hormone receptor–positive, HER2–negative breast cancer while receiving adjuvant endocrine therapy should be offered an alternative endocrine therapy except in cases of visceral crisis or rapidly progressive disease (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

##### Recommendation 4.3

Endocrine therapy for men with advanced or metastatic, hormone receptor–positive, HER2–negative breast cancer may be sequenced as in women (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** Metastatic breast cancer in men is treated with the same endocrine therapies used to treat metastatic breast cancer in women. Endocrine treatment options include tamoxifen, an AI with a GnRH agent, and fulvestrant. There is no evidence from clinical trials in men with advanced or metastatic breast cancer to

inform clinical questions regarding the optimal sequencing of endocrine therapies. In general, the Expert Panel recommends using the therapies in the order listed above. The recommendations offered here reflect the best clinical opinion of the Expert Panel members based on their personal clinical experience managing male breast cancer, and based on extrapolation from studies of endocrine therapy conducted in women with advanced breast cancer.<sup>35</sup> As with women, men experiencing visceral crisis and/or rapidly progressive disease should consider chemotherapy as an initial treatment option.

Available data from case reports and small case series do not support strong conclusions about the use of monotherapy versus combination endocrine therapy in men with metastatic breast cancer, but some studies<sup>7,8</sup> have reported greater responses when an AI is combined with a GnRH analog. Based on this information, the Expert Panel suggests combining AIs with GnRH analogs but acknowledges that single-agent AIs may be reasonable for patients unlikely to tolerate combined therapy who have unmeasurable estrogen levels. A pooled analysis of case reports and case series conducted by Zagouri et al<sup>15</sup> suggests a promising role for fulvestrant.

Among women with hormone receptor–positive metastatic breast cancer, endocrine therapy is often combined with CDK inhibitor therapy, because multiple studies have demonstrated that this treatment increases the response rate and prolongs progression-free survival.<sup>36,37</sup> Data regarding the benefits and adverse effects of CDK4/6 inhibitors in men with metastatic breast cancer are sparse, but selected trials of these targeted agents have included men and small case series have been reported. Consequently, the FDA granted approval for the use of one CDK4/6 inhibitor in men with metastatic hormone receptor–positive breast cancer (<https://www.ascopost.com/News/59909>). The Expert Panel suggests that it would be reasonable to use CDK4/6 inhibitors in men as they are used in women.

#### CLINICAL QUESTION 5

What is the role of targeted therapy in the treatment of men with advanced or metastatic breast cancer? Note that “targeted therapy” refers to treatments that target HER2–positive tumors, PD-L1–positive tumors, and patients carrying pathogenic germline *BRCA 1/2* mutations; endocrine therapies are addressed elsewhere in the guideline.

##### Recommendation 5

Targeted therapy guided by hormone receptor (HR), HER2, programmed death ligand 1 (PDL-1), PIK3CA, and germline *BRCA* mutation status may be used in the treatment of advanced or metastatic male breast cancer using the same indications and combinations that are offered to women (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong). (Targeted

therapy based on hormone receptor status is addressed in Recommendations 4.1 to 4.3.)

**Literature review and analysis.** There is no evidence from randomized clinical trials in men with breast cancer to inform clinical questions regarding the use of targeted systemic therapy in combination with endocrine therapy in the treatment of advanced or metastatic male breast cancer. Other targeted nonendocrine therapies have recently been approved (eg, alpelisib), and the Panel believes they are likely to be similarly effective in men as in women. These recommendations represent the best clinical opinion of the Expert Panel based on personal experience in the management of male breast cancer and extrapolation from studies conducted in women.<sup>38-41</sup>

### CLINICAL QUESTION 6

What is the optimal approach to managing the toxicity of endocrine therapy in men with breast cancer?

#### Recommendation 6.1

Management of endocrine therapy toxicity is similar to the approach used for women (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

#### Recommendation 6.2

Testosterone/androgen supplementation should not be used by men with breast cancer (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** There is no evidence from clinical trials in men with breast cancer to inform clinical questions regarding the optimal management of endocrine therapy toxicity in men. The recommendations offered represent the best clinical opinion of the Expert Panel members based on personal experience in the management of male breast cancer, and, for management of adverse effects such as hot flashes that are commonly experienced by both men and women being treated for breast cancer, based on extrapolation from studies of women and a study of men being treated for prostate cancer.<sup>42</sup>

The systematic review conducted for this consensus guideline identified four studies that addressed the prevalence and/or management of endocrine therapy adverse effects.<sup>17-20</sup> These studies found an increased incidence of thrombotic events in men treated with tamoxifen, more than 80% of which occurred in the first 18 months after the start of treatment<sup>17</sup>; a high rate of treatment discontinuation due to adverse effects (eg, hot flashes, weight gain, sexual dysfunction) among men with breast cancer who received tamoxifen<sup>18</sup>; a substantial prevalence of sexual dysfunction and hormonal symptoms among male breast cancer survivors<sup>19</sup>; and a greater risk of cancer recurrence and death among men with breast cancer who were less adherent to tamoxifen treatment.<sup>20</sup> With respect to the management of hot flashes in men, venlafaxine has been shown to be an effective treatment of hot flashes in men with prostate cancer who were receiving GnRH analogs.<sup>42</sup> This drug may

be effective in reducing hot flashes in men with breast cancer treated with tamoxifen or GnRH analogs. With respect to testosterone, its conversion to estrogen by aromatase raises concern about its use among men with hormone receptor–positive breast cancer. Use of exogenous testosterone for hypogonadism among men with a history of hormone receptor–positive breast cancer should follow an informed discussion about the potential benefits and risks of this treatment, considering the patient's residual risk of breast cancer recurrence.

### CLINICAL QUESTION 7

What guidance around follow-up and management should be available to men who have been previously treated for breast cancer?

#### Recommendation 7

Physicians should counsel patients about the symptoms of recurrence, including new lumps, bone pain, chest pain, dyspnea, abdominal pain, or persistent headaches. The risk of breast cancer recurrence continues through 15 years after primary treatment and beyond. Continuity of care for patients with breast cancer is recommended and should be performed by a physician experienced in the surveillance of patients with cancer and in breast examination, including the examination of irradiated breasts<sup>43</sup> (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** Recommendation 7 is adapted from the guideline for women: "Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update."<sup>43</sup> There is no evidence from clinical trials in men with breast cancer to inform clinical questions regarding the optimal post-treatment surveillance and management after primary treatment. The recommendations offered represent the best clinical opinion of the Expert Panel members based on personal experience in the management of male breast cancer. Follow-up care for men who are treated for breast cancer should generally be similar to care provided for women with breast cancer. As noted previously, there is no clear role for the use of bone-modifying agents to prevent recurrence in men with breast cancer. However, men who are receiving a GnRH analog and an AI are at increased risk of bone loss; thus, monitoring bone mineral density in this group is warranted.<sup>44</sup>

### CLINICAL QUESTION 8

What testing is recommended for the detection of breast cancer after curative-intent primary therapy for patients who are not germline mutation carriers of breast cancer susceptibility genes?

#### Recommendation 8

Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy, if

technically feasible, regardless of genetic predisposition (Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Literature review and analysis.** There is no evidence from clinical trials in men with breast cancer to inform clinical questions regarding the usefulness or necessity of ipsilateral mammography in men with a history of breast cancer that was treated with lumpectomy. The recommendation offered represents the best clinical opinion of the Expert Panel members based on personal experience in the management of male breast cancer. Use of contralateral annual mammography for men with a history of breast cancer is discussed in the section Draft Recommendations That Did Not Reach the Required 75% Consensus Threshold, because the Expert Panel did not reach consensus on this topic.

### CLINICAL QUESTION 9

How should post-treatment surveillance recommendations differ for men with breast cancer who carry predisposing germline mutations in breast cancer susceptibility genes?

#### Recommendation 9.1

Contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

#### Recommendation 9.2

Breast magnetic resonance imaging is not recommended routinely in men with a history of breast cancer (Type: formal consensus; Evidence quality: low; Strength of recommendation: moderate).

**Literature review and analysis.** Among men carrying *BRCA1* and *BRCA2* mutations, the cumulative risk of breast cancer by age 70 years was 1.2% and 6.8%, respectively.<sup>45</sup> These values are lower than the risks experienced by women carrying *BRCA1* and *BRCA2* mutations but are still substantially elevated over the average man's risk. Consequently, the Expert Panel recommended that contralateral mammography may be offered. The recommendation against routine breast magnetic resonance imaging was based in part on (1) the relatively small amount of breast tissue present in most men, (2) the lack of data demonstrating an improvement in survival for this screening test among women, and (3) the potential for false positives.

### CLINICAL QUESTION 10

Should referral for genetic counseling and genetic testing for germline mutations be recommended for male patients with breast cancer?

#### Recommendation 10

Male patients with breast cancer should be offered genetic counseling and genetic testing for germline mutations

(Type: formal consensus; Evidence quality: low; Strength of recommendation: strong).

**Literature review and analysis.** Previous population-based studies have found that 0% to 4% of men with breast cancer have mutations of the *BRCA1* gene, and 4% to 16% have mutations of the *BRCA2* gene.<sup>46-48</sup> In contrast, mutations of the *BRCA1* and *BRCA2* tumor-suppressor genes have been identified in 5% to 10% of women with breast cancer.<sup>49</sup> Mutations in other genes, such as *CHEK2*, *PALB2*, and *PTEN*, are less common but also appear to confer elevated breast cancer risk among men.<sup>50-52</sup> When considering all these genes, > 20% of male patients with breast cancer may carry an identifiable inherited risk factor for breast cancer. Consequently, the Expert Panel recommends genetic counseling and consideration of genetic testing for all male patients with breast cancer. Identification of an inherited risk factor could (1) influence screening recommendations for other types of cancer, (2) lead to testing of family members for inherited risk factors, and (3) identify treatment opportunities for patients with metastatic breast cancer (eg, poly-ADP ribose polymerase inhibitors).<sup>39,40</sup>

### DRAFT RECOMMENDATIONS THAT DID NOT REACH THE REQUIRED 75% CONSENSUS THRESHOLD

Two draft recommendations did not exceed the 75% consensus agreement threshold required for adoption into the formal guideline statement: (1) contralateral annual mammography in men without a predisposing genetic mutation and (2) chemoprevention. In accordance with the modified Delphi approach used by ASCO,<sup>3</sup> the Expert Panel could not issue formal consensus recommendations for these clinical questions. Regarding the draft recommendation pertaining to the routine use of contralateral annual mammography, panel members and reviewers expressed mixed views. The discussion centered around the perceived incidence of contralateral second primary breast cancer relative to the perceived burden of mammography. Prior studies have suggested that the lifetime risk of a second primary breast cancer among men is approximately 2%.<sup>27,53</sup> While this is higher than the risk of breast cancer among the general population of men, it is lower than the risk of breast cancer among the general population of women. Gao et al<sup>54</sup> reported a similar cancer detection rate when screening high-risk men and average-risk women, but the population of screened men was likely not representative of all men with a history of breast cancer, and the study was a single-institution retrospective study from a tertiary-care academic medical center. In addition, the study did not evaluate the impact of screening on survival, so the benefit of such screening remains uncertain.

Regarding the draft recommendation for the use of chemoprevention in men with (1) noninvasive breast cancer, (2) invasive breast cancer for whom adjuvant therapy is not otherwise indicated, and (3) no history of breast cancer who

have a germline pathogenic or likely pathogenic variant (mutation) in a *BRCA 1/2* gene, the level of agreement was 74%. Comments from the Consensus Panel suggested that the wording of the draft guideline was confusing and that consensus regarding the use of chemoprevention in this setting did not exist.

### SUMMARY AND DIRECTIONS FOR FUTURE RESEARCH

This formal consensus ASCO guideline provides practice recommendations on a range of aspects related to the management of male breast cancer, including endocrine therapy, targeted therapy, genetic testing, management of treatment-related adverse effects, and post-treatment surveillance. A multidisciplinary Consensus Panel, composed of 13 members from an ASCO Expert Panel and an additional 21 content experts, rated its agreement with a series of 18 recommendations. Most of the draft guidelines were endorsed by the Consensus Panel during the first round of voting. Only four draft guidelines were reviewed during the second round of voting, and of these, only two did not reach or exceed the a priori–defined 75% agreement threshold.

To date, recommendations for the treatment of male breast cancer have been extrapolated from the results of clinical trials that enrolled only women,<sup>2,55</sup> from small case series, or from personal clinical experience in treating men with breast cancer.<sup>56</sup> This ASCO formal consensus guideline is no exception. Clearly, additional research is needed on a broad array of topics concerning the management of male breast cancer,<sup>57</sup> even those for which agreement on the treatment approach was high. Fortunately, several current treatment trials are enrolling both women and men, after many years of encouragement from both patient organizations (see <https://malebreastcancercoalition.org>) and the International Male Breast Cancer Program. In that regard, the FDA recently issued draft guidance for industry encouraging the inclusion of men in clinical trials studying treatments for breast cancer. The FDA recommended that, “when males have not been included...in clinical trials for a specific breast cancer drug: it may be possible to extrapolate findings to include patients with the FDA-approved indication for the drug where no difference in efficacy or safety is anticipated between males and females based on the mechanism of action of a drug” (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment>). Concern for differential efficacy in males versus females is greatest with endocrine therapies, making the inclusion of men in clinical trials of endocrine treatments particularly important.

### PATIENT AND CLINICIAN COMMUNICATION

For recommendations and strategies to optimize patient-clinician communication, see the ASCO Consensus Guideline on Patient-Clinician Communication.<sup>58</sup> This ASCO

guideline offers a series of recommendations on core skills and tasks to improve communication and suggests a number of concrete implementation strategies. One recommendation that is particularly relevant to clinical encounters with male patients with breast cancer is the need for clinicians to “Remain aware that members of...marginalized populations have an increased likelihood of having had negative past health care experiences, including feeling...alienated....”<sup>58(p3628)</sup>

The literature on male breast cancer survivorship is sparse<sup>59-64</sup>; however, several qualitative studies have suggested that feelings of emasculation associated with having a “woman’s disease,”<sup>65</sup> sexual stigmatization, and ignorance of the disease<sup>65</sup> are common among men with breast cancer.<sup>60,63</sup> The lack of male-specific educational information<sup>59</sup> and limited opportunities for men with breast cancer to talk with other men with breast cancer likely contribute to their sense of isolation and cancer-related distress.<sup>62</sup> Fortunately, some of these problems can be ameliorated in relatively straightforward ways. Brain et al<sup>59</sup> and Williams et al<sup>62</sup> have suggested several practical solutions: (1) inclusion of booklets or leaflets on male breast cancer to improve information and awareness, (2) providing male patients a photograph of a male mastectomy to show men what they will look like after the surgery, (3) telephone help-lines and referrals to other sources of support, and (4) efforts to increase public awareness of male breast cancer.

### HEALTH DISPARITIES

ASCO clinical practice guidelines represent expert recommendations for best practices in disease management. However, it is important to note that many patients have limited access to medical care, and that racial and ethnic disparities contribute significantly to this problem in the United States and around the world. Patients with cancer who are members of racial/ethnic minorities suffer disproportionately from inferior outcomes, experience more obstacles to receiving optimal care, are more likely to be uninsured or underinsured, and are at greater risk of receiving care of poor quality. Geographic location (ie, a long distance from appropriate treatment facilities) may also impair access to optimal care. Most of the studies that have identified disparities in the care provided to and outcomes experienced by patients with breast cancer have focused on women.

The electronic literature search conducted to inform this section of the male breast cancer guideline identified eight articles (from a total of 88 abstracts) on the topic of health disparities. Studies of disparities among male patients with breast cancer have yielded inconsistent results.<sup>66-68</sup> However, the small sample sizes and inherent selection bias associated with these observational studies of patients with male breast cancer are substantial limitations for these studies. The Expert Panel believes that disparities are just

as likely to occur in men as in women, and therefore recommends: (1) awareness of the disparities and barriers to accessing care when considering this clinical practice guideline, and (2) that health care providers should strive to deliver the highest level of cancer care to all populations, including those that are more vulnerable. The Expert Panel also notes that transgender individuals have not been evaluated in most prior studies of breast cancer disparities and believes that these individuals may also be at risk of experiencing disparities. Recent studies have begun to explore the risk of developing breast cancer among trans women and trans men.<sup>69</sup> The Expert Panel believes that the treatment of breast cancer should be the same for transgender women, with the notable exception that exogenous estrogen is not recommended for patients with a history of breast cancer.

### **MULTIPLE CHRONIC CONDITIONS**

Creating evidence-based recommendations to inform the oncology care of patients with multiple chronic conditions (MCCs)—where patients have two or more serious non-cancer conditions—is challenging. Patients with MCCs are a complex and heterogeneous population, making it difficult to account for all the possible permutations and to develop specific recommendations for cancer care. In addition, the best available evidence for treating cancer often comes from clinical trials that exclude patients with MCCs. This is done to avoid potential interaction effects and confounding of results, but it limits the ability to generalize outcomes data from these studies to patients with MCCs and constrains expert groups' efforts to make recommendations for this heterogeneous patient population. The Expert Panel believes that any treatment plan should consider the complexity and uncertainty created by the presence of MCCs and highlights the importance of shared decision making that incorporates the goals of the patient as well as the input of the specialists treating the patient's other chronic conditions. The need for clinicians to consider all relevant chronic conditions when formulating a treatment and follow-up plan for a new breast cancer diagnosis is the same whether the patient is male or female. That having been said, the Expert Panel believes it is important to note that the average age of a new breast cancer diagnosis is five years older for men (67 years) than for women (62 years). Consequently, clinicians should expect a higher comorbidity burden due to age among men with breast cancer.

### **COST IMPLICATIONS**

Increasingly, individuals with cancer are required to pay a larger proportion of their treatment costs through deductibles and coinsurance. Higher patient out-of-pocket costs are a barrier to initiating and adhering to recommended cancer treatments. Discussion of cost can be an important part of shared decision making. Clinicians should discuss with patients the use of less expensive alternatives

when it is practical and feasible and when there are two or more treatment options that are comparable in terms of benefits and harms.

Patient out-of-pocket costs may vary depending on insurance coverage. Coverage may originate in the medical or pharmacy benefit, which may have different cost-sharing arrangements. Patients should be aware that different products may be preferred or covered by their particular insurance plan. Even with the same insurance plan, the price may vary among different pharmacies. When discussing financial issues and concerns, patients should be made aware of any financial counseling services available to address this complex and heterogeneous landscape.

Providers treating male patients with breast cancer should be aware that men could be at greater risk of being denied coverage for some expensive breast cancer treatments, because coverage determinations focused only on women, and appeals of coverage denials may be more common.

As part of the guideline development process, ASCO may opt to search the literature for published cost-effectiveness analyses that might inform the relative value of available treatment options. Excluded from consideration are cost-effectiveness analyses that lack contemporary cost data; agents that are not currently available in either the United States or Canada; and/or studies that are industry sponsored. No cost-effectiveness analyses were identified to inform the topic.

### **EXTERNAL REVIEW AND OPEN COMMENT**

The draft recommendations were released to the public for open comment from September 3, 2019, through September 17, 2019. Response categories of "Agree as written", "Agree with suggested modifications", and "Disagree. See comments" were captured for every proposed recommendation, with 15 written comments received. Respondents either agreed or agreed with slight modifications with 13 of the 16 recommendations; one respondent disagreed with three of the recommendations; another respondent disagreed with a single recommendation. Expert Panel members reviewed comments from all sources and determined whether to maintain original draft recommendations, revise with minor language changes, or consider major recommendation revisions. All changes were incorporated prior to Clinical Practice Guidelines Committee review and approval.

### **GUIDELINE IMPLEMENTATION**

ASCO guidelines are developed for implementation across health settings. Each ASCO guideline includes a member from ASCO's Practice Guideline Implementation Network (PGIN) on the Expert Panel. The additional role of this PGIN representative on the Guideline Panel is to assess the suitability of the recommendations to implementation in the

community setting, but also to identify any other barrier to implementation of which a reader should be aware. Barriers to implementation include the need to increase awareness of the guideline recommendations among front-line practitioners and survivors of cancer and caregivers, and also to provide adequate services in the face of limited resources. The guideline Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely through the ASCO PGIN. ASCO guidelines are posted on the ASCO Web site and most often published in *Journal of Clinical Oncology* and a summary in *Journal of Oncology Practice*.

**ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should have the opportunity to participate.**

### ADDITIONAL RESOURCES

More information, including a supplement with additional evidence tables, slide sets, and clinical tools and resources,

is available at [www.asco.org/breast-cancer-guidelines](http://www.asco.org/breast-cancer-guidelines). Patient information is available at [www.cancer.net](http://www.cancer.net).

### RELATED ASCO GUIDELINES

- Patient-Clinician Communication<sup>58</sup> (<http://ascopubs.org/doi/10.1200/JCO.2017.75.2311>)
- Prostate Cancer Survivorship Care<sup>70</sup> (<https://ascopubs.org/doi/10.1200/JCO.2014.60.2557>)
- Breast Cancer Follow-Up and Management After Primary Treatment<sup>43</sup> (<http://ascopubs.org/doi/10.1200/JCO.2012.45.9859>)
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer<sup>38</sup> (<http://ascopubs.org/doi/10.1200/JCO.2018.79.2697>)

### AFFILIATIONS

<sup>1</sup>Dana-Farber Cancer Institute, Boston, MA

<sup>2</sup>ASCO, Alexandria, VA

<sup>3</sup>University of Alaska, Anchorage, AK

<sup>4</sup>Chamalimaud Clinical Centre/Chamalimaud Foundation, Lisbon, Portugal

<sup>5</sup>University of California, Irvine, Orange, CA

<sup>6</sup>Brigham and Women's Hospital, Boston, MA

<sup>7</sup>Duke University Medical Center, Durham, NC

<sup>8</sup>University of Southern California, Los Angeles, CA

<sup>9</sup>Washington University, Saint Louis, MO

<sup>10</sup>Mayo Clinic, Rochester, MN

<sup>11</sup>Icahn School of Medicine at Mount Sinai, New York, NY

<sup>12</sup>University of Michigan, Ann Arbor, MI

<sup>13</sup>University of Washington, Seattle, WA

<sup>14</sup>MD Anderson Cancer Center, Houston, TX

### CORRESPONDING AUTHOR

American Society of Clinical Oncology, 2318 Mill Rd, Suite 800, Alexandria, VA 22314; e-mail: [guidelines@asco.org](mailto:guidelines@asco.org).

### EQUAL CONTRIBUTION

M.J.H. and S.H.G. were Expert Panel co-chairs.

Clinical Practice Guidelines Committee approval: November 22, 2019

### EDITOR'S NOTE

This American Society of Clinical Oncology (ASCO) Clinical Practice Guideline provides recommendations, with comprehensive review and analyses of the relevant literature for each recommendation. Additional information, including a supplement with additional evidence tables, slide sets, clinical tools and resources, and links to patient information at

[www.cancer.net](http://www.cancer.net), is available at [www.asco.org/breast-cancer-guidelines](http://www.asco.org/breast-cancer-guidelines).

### AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT

Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI <https://doi.org/10.1200/JCO.19.03120>.

### AUTHOR CONTRIBUTIONS

**Conception and design:** Michael J. Hassett, Mark R. Somerfield, Fatima Cardoso, Dylan C. Kwait, Catherine Van Poznak, Sharon H. Giordano

**Administrative support:** Mark R. Somerfield

**Collection and assembly of data:** Mark R. Somerfield, Fatima Cardoso, Kari J. Kansal, Dylan C. Kwait

**Data analysis and interpretation:** All authors

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

### ACKNOWLEDGMENT

The Expert Panel wishes to thank Bruno Ferrari, MD, and Zeina Nahleh, MD, the ASCO Clinical Practice Guidelines Committee, and ASCO's Erin Kennedy for their thoughtful reviews and insightful comments on this guideline. Thanks also to Margaret Beckwith, PhD and Beverly Moy, MD of the National Cancer Institute's Physician Data Query and Cynthia Boggess of Cancer Information Analysis and Tracking for assistance with the literature search conducted for this ASCO guideline. Thanks, finally, to Brittany E. Harvey for assistance with construction of evidence summary tables, and to Shannon E. McKernin for editorial review of earlier drafts of the guideline manuscript.

### REFERENCES

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. *CA Cancer J Clin* 69:7-34, 2019
2. Giordano SH: Breast cancer in men. *N Engl J Med* 378:2311-2320, 2018
3. Loblaw DA, Prestrud AA, Somerfield MR, et al: American Society of Clinical Oncology clinical practice guidelines: Formal systematic review-based consensus methodology. *J Clin Oncol* 30:3136-3140, 2012

4. Henry NL, Somerfield MR, Abramson VG, et al: Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: Update of the ASCO endorsement of the Cancer Care Ontario guideline. *J Clin Oncol* 37:1965-1977, 2019
5. Di Lauro L, Pizzuti L, Barba M, et al: Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: Results from a pooled analysis. *J Hematol Oncol* 8:53, 2015
6. Di Lauro L, Vici P, Barba M, et al: Antiandrogen therapy in metastatic male breast cancer: Results from an updated analysis in an expanded case series. *Breast Cancer Res Treat* 148:73-80, 2014
7. Di Lauro L, Vici P, Del Medico P, et al: Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. *Breast Cancer Res Treat* 141:119-123, 2013
8. Doyen J, Italiano A, Largillier R, et al: Aromatase inhibition in male breast cancer patients: Biological and clinical implications. *Ann Oncol* 21:1243-1245, 2010
9. Eggemann H, Altmann U, Costa SD, et al: Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. *J Cancer Res Clin Oncol* 144:337-341, 2018
10. Eggemann H, Ignatov A, Smith BJ, et al: Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. *Breast Cancer Res Treat* 137:465-470, 2013
11. Fogh S, Hirsch AE, Langmead JP, et al: Use of tamoxifen with postsurgical irradiation may improve survival in estrogen and progesterone receptor-positive male breast cancer. *Clin Breast Cancer* 11:39-45, 2011
12. Giordano SH, Perkins GH, Broglio K, et al: Adjuvant systemic therapy for male breast carcinoma. *Cancer* 104:2359-2364, 2005
13. Margaria E, Chiusa L, Ferrari L, et al: Therapy and survival in male breast carcinoma: A retrospective analysis of 50 cases. *Oncol Rep* 7:1035-1039, 2000
14. Wenhui Z, Shuo L, Dabe T, et al: Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment. *Eur J Endocrinol* 171:527-533, 2014
15. Zagouri F, Sergentanis TN, Chrysikos D, et al: Fulvestrant and male breast cancer: A pooled analysis. *Breast Cancer Res Treat* 149:269-275, 2015
16. Zagouri F, Sergentanis TN, Koutoulidis V, et al: Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: A case series. *Br J Cancer* 108:2259-2263, 2013
17. Eggemann H, Bernreiter AL, Reinisch M, et al: Tamoxifen treatment for male breast cancer and risk of thromboembolism: Prospective cohort analysis. *Br J Cancer* 120:301-305, 2019
18. Pemmaraju N, Munsell MF, Hortobagyi GN, et al: Retrospective review of male breast cancer patients: Analysis of tamoxifen-related side-effects. *Ann Oncol* 23:1471-1474, 2012
19. Ruddy KJ, Giobbie-Hurder A, Giordano SH, et al: Quality of life and symptoms in male breast cancer survivors. *Breast* 22:197-199, 2013
20. Xu S, Yang Y, Tao W, et al: Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. *Breast Cancer Res Treat* 136:495-502, 2012
21. Arslan UY, Oksüzöglü B, Ozdemir N, et al: Outcome of non-metastatic male breast cancer: 118 patients. *Med Oncol* 29:554-560, 2012
22. Cutuli B, Le-Nir CC, Serin D, et al: Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. *Crit Rev Oncol Hematol* 73:246-254, 2010
23. Donegan WL, Redlich PN, Lang PJ, et al: Carcinoma of the breast in males: A multiinstitutional survey. *Cancer* 83:498-509, 1998
24. Harlan LC, Zujewski JA, Goodman MT, et al: Breast cancer in men in the United States: A population-based study of diagnosis, treatment, and survival. *Cancer* 116:3558-3568, 2010
25. Goss PE, Reid C, Pintilie M, et al: Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. *Cancer* 85:629-639, 1999
26. Cardoso F, Bartlett JMS, Slaets L, et al: Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. *Ann Oncol* 29:405-417, 2018
27. Avinien A, Curtis RE, Ron E: Risk of subsequent cancer following breast cancer in men. *J Natl Cancer Inst* 94:1330-1332, 2002
28. Grenader T, Goldberg A, Shavit L: Second cancers in patients with male breast cancer: A literature review. *J Cancer Surviv* 2:73-78, 2008
29. Mitri ZI, Jackson M, Garby C, et al: BRCAPRO 6.0 model validation in male patients presenting for BRCA testing. *Oncologist* 20:593-597, 2015
30. Pritzlaff M, Summerour P, McFarland R, et al: Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results. *Breast Cancer Res Treat* 161:575-586, 2017
31. Burstein HJ, Lacchetti C, Anderson H, et al: Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. *J Clin Oncol* 37:423-438, 2019
32. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 381:805-816, 2013 [Erratum: *Lancet* 381:9869, 2013]
33. Anelli TF, Anelli A, Tran KN, et al: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. *Cancer* 74:74-77, 1994
34. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. *Lancet* 386:1353-1361, 2015
35. Rugo HS, Rumble RB, Macrae E, et al: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. *J Clin Oncol* 34:3069-3103, 2016
36. Turner NC, Ro J, André F, et al: Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* 373:209-219, 2015
37. Cristofanilli M, Turner NC, Bondarenko I, et al: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol* 17:425-439, 2016 [Erratum: *Lancet Oncol* 17:431, 434, 435, 2016]
38. Giordano SH, Temin S, Chandrapaty S, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. *J Clin Oncol* 36:2736-2740, 2018
39. Litton JK, Rugo HS, Ettl J, et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med* 379:753-763, 2018
40. Robson M, Im SA, Senkus E, et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med* 377:523-533, 2017 [Erratum: *N Engl J Med*, 2017]
41. Schmid P, Adams S, Rugo HS, et al: Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med* 379:2108-2121, 2018
42. Irani J, Salomon L, Oba R, et al: Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flashes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A double-blind, randomised trial. *Lancet Oncol* 11:147-154, 2010
43. Khatcheressian JL, Hurley P, Bantug E, et al: Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 31:961-965, 2013

44. Gralow JR, Biermann JS, Farooki A, et al: NCCN Task Force report: Bone health in cancer care. *J Natl Compr Canc Netw* 11:S1-S50, quiz S51, 2013
  45. Tai YC, Domchek S, Parmigiani G, et al: Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 99:1811-1814, 2007
  46. Basham VM, Lipscombe JM, Ward JM, et al: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. *Breast Cancer Res* 4:R2, 2002
  47. Friedman LS, Gayther SA, Kurosaki T, et al: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. *Am J Hum Genet* 60:313-319, 1997
  48. Ottini L, Masala G, D'Amico C, et al: BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: A population-based study in Italy. *Cancer Res* 63:342-347, 2003
  49. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am J Hum Genet* 72:1117-1130, 2003
  50. Fackenthal JD, Marsh DJ, Richardson AL, et al: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. *J Med Genet* 38:159-164, 2001
  51. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al: Low-penetrance susceptibility to breast cancer due to CHEK2(\*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nat Genet* 31:55-59, 2002
  52. Rahman N, Seal S, Thompson D, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 39:165-167, 2007
  53. Dong C, Hemminki K: Second primary breast cancer in men. *Breast Cancer Res Treat* 66:171-172, 2001
  54. Gao Y, Goldberg JE, Young TK, et al: Breast cancer screening in high-risk men: A 12-year longitudinal observational study of male breast imaging utilization and outcomes. *Radiology* 293:282-291, 2019
  55. Gucalp A, Traina TA, Eisner JR, et al: Male breast cancer: A disease distinct from female breast cancer. *Breast Cancer Res Treat* 173:37-48, 2019
  56. Korde LA, Zujewski JA, Kamin L, et al: Multidisciplinary meeting on male breast cancer: Summary and research recommendations. *J Clin Oncol* 28:2114-2122, 2010
  57. Duma N, Hoversten KP, Ruddy KJ: Exclusion of male patients in breast cancer clinical trials. *JNCI Cancer Spectrum* 2:pyk018, 2018
  58. Gilligan T, Coyle N, Frankel RM, et al: Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 35:3618-3632, 2017
  59. Brain K, Williams B, Iredale R, et al: Psychological distress in men with breast cancer. *J Clin Oncol* 24:95-101, 2006
  60. France L, Michie S, Barrett-Lee P, et al: Male cancer: A qualitative study of male breast cancer. *Breast* 9:343-348, 2000
  61. Iredale R, Brain K, Williams B, et al: The experiences of men with breast cancer in the United Kingdom. *Eur J Cancer* 42:334-341, 2006
  62. Williams BG, Iredale R, Brain K, et al: Experiences of men with breast cancer: An exploratory focus group study. *Br J Cancer* 89:1834-1836, 2003
  63. Quincey K, Williamson I, Winstanley S: 'Marginalised malignancies': A qualitative synthesis of men's accounts of living with breast cancer. *Soc Sci Med* 149: 17-25, 2016
  64. Donovan T, Flynn M: What makes a man a man? The lived experience of male breast cancer. *Cancer Nurs* 30:464-470, 2007
  65. Midding E, Halbach SM, Kowalski C, et al: Men with a "woman's disease": Stigmatization of male breast cancer patients—A mixed methods analysis. *Am J Men Health* 12:2194-2207, 2018
  66. Crew KD, Neugut AI, Wang X, et al: Racial disparities in treatment and survival of male breast cancer. *J Clin Oncol* 25:1089-1098, 2007
  67. Sun HF, Zhao Y, Gao SP, et al: Clinicopathological characteristics and survival outcomes of male breast cancer according to race: A SEER population-based study. *Oncotarget* 8:69680-69690, 2017
  68. Sineshaw HM, Freedman RA, Ward EM, et al: Black/white disparities in receipt of treatment and survival among men with early-stage breast cancer. *J Clin Oncol* 33:2337-2344, 2015
  69. de Blok CJM, Wierjes CM, Nota NM, et al: Breast cancer risk in transgender people receiving hormone treatment: Nationwide cohort study in the Netherlands. *BMJ* 365:11652, 2019
  70. Resnick MJ, Lacchetti C, Bergman J, et al: Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol* 33:1078-1085, 2015
-

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

### Management of Male Breast Cancer: ASCO Guideline

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/journal/jco/site/ifc](http://ascopubs.org/journal/jco/site/ifc).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

#### **Fatima Cardoso**

**Consulting or Advisory Role:** Roche, Novartis, Pfizer, AstraZeneca, Teva, Astellas Pharma, Merus, Celgene, Eisai, Daiichi Sankyo, Genentech, Merck Sharp & Dohme, Sanofi, Pierre Fabre, MacroGenics, Amgen, GE Healthcare, GlaxoSmithKline, Mylan, Mundipharma, Seattle Genetics, Samsung Bioepis, Medscape, Prime Oncology

**Travel, Accommodations, Expenses:** Pfizer, Roche, AstraZeneca

#### **Kari J. Kansal**

**Consulting or Advisory Role:** Silk Road Medical (I)

**Travel, Accommodations, Expenses:** Silk Road Medical (I)

#### **Dylan C. Kwait**

**Honoraria:** Hologic

#### **Jennifer K. Plichta**

**Research Funding:** Color Genomics

#### **Anna Roshal**

**Consulting or Advisory Role:** Boston Gene

#### **Kathryn J. Ruddy**

**Stock and Other Ownership Interests:** Merck, Pfizer

**Patents, Royalties, Other Intellectual Property:** My husband is a co-inventor of technology licensed by Mayo Clinic to AliveCor (Mountain View, CA), which makes a smartphone-enabled remote ECG monitoring system (I).

#### **Joshua D. Safer**

**Employment:** Parexel (I)

**Consulting or Advisory Role:** Endo Pharmaceuticals

#### **Catherine Van Poznak**

**Research Funding:** Bayer (Inst)

**Patents, Royalties, Other Intellectual Property:** UpToDate

## APPENDIX

**TABLE A1.** Management of Male Breast Cancer: ASCO Guideline Expert Panel Membership

<b>Name</b>	<b>Affiliation/Institution</b>	<b>Role/Area of Expertise</b>
Sharon H. Giordano, MD, MPH (co-chair)	MD Anderson Cancer Center, Houston, TX	Medical oncology/health services research
Michael J. Hassett, MD, MPH (co-chair)	Dana-Farber Cancer Institute, Boston, MA	Medical oncology/health services research
Elisha R. Baker, PhD (patient representative)	University of Alaska, Anchorage, AK	Patient advocacy
Fatima Cardoso, MD	Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal	Medical oncology
Kari J. Kansal, MD	University of California, Irvine, Orange, CA	Surgical oncology
Dylan C. Kwait, MD	Brigham and Women's Hospital, Boston, MA	Diagnostic radiology
Jennifer K. Plichta, MD, MS	Duke University Medical Center, Durham, NC	Surgical oncology
Charité Ricker, MS	University of Southern California, Los Angeles, CA	Genetic counseling
Anna Roshal, MD (PGIN representative)	Washington University, Saint Louis, MO	Medical oncology
Kathryn J. Ruddy, MD, MPH	Mayo Clinic, Rochester, MN	Medical oncology
Joshua D. Safer, MD	Icahn School of Medicine at Mount Sinai, New York, NY	Endocrinology
Catherine Van Poznak, MD	University of Michigan, Ann Arbor, MI	Medical oncology
Rachel L. Yung, MD	University of Washington, Seattle, WA	Medical oncology
Mark R. Somerfield, PhD	American Society of Clinical Oncology(ASCO)	ASCO Practice Guidelines staff (health research methods)

Abbreviation: PGIN, Practice Guideline Implementation Network.